Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials

• Κύριοι συγγραφείς: Melinda J. Gooderham (Συγγραφέας), Michael R. Ardern‐Jones (Συγγραφέας), Emma Guttman‐Yassky (Συγγραφέας), Mahreen Ameen (Συγγραφέας), Eric L. Simpson (Συγγραφέας), Gary Chan (Συγγραφέας), Pinaki Biswas (Συγγραφέας), Wing S. Chiu (Συγγραφέας), Melissa Watkins (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2023-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract Background Patients with moderate‐to‐severe atopic dermatitis (AD) refractory to topical therapy might require treatment with systemic therapies, including biologics. Objectives To assess the efficacy and safety of abrocitinib monotherapy in patients who previously received systemic therapi...